These are the stocks posting the largest moves before the bell.Market Insiderread more
An oil processing facility at Abqaiq and the nearby Khurais oil field was attacked on Saturday.Marketsread more
"There is reason to believe that we know the culprit," Trump said in a post on Twitter.Politicsread more
An extended Saudi oil outage could push Brent crude prices north of $75 per barrel, Goldman Sachs warned clients.Marketsread more
As investors worry about oil supply, airline and cruise ship stocks are getting hit on Monday, while some energy stocks are shooting upward.Marketsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Brent crude surged by as much as 19.5% to reach $71.95 per barrel on Monday, the biggest intra-day jump since the Gulf War in 1991.Oilread more
U.S. stock futures are under pressure Monday as oil prices spike after Saturday's coordinated strikes on key Saudi oil interests.Marketsread more
In the past few weeks, the S&P 500 has waged a 6% rally, pulling within 1% of its late-July record high by Friday's close.Trading Nationread more
The strike, depending on its length, could easily cost GM hundreds of millions of dollars. The last time the union declared a strike at GM was in 2007.Autosread more
Consumers in the U.S. prefer Apple's more expensive models, while the standard iPhone 11 appears to be more attractive to buyers in China, according to Kuo.Technologyread more
Canada's Valeant Pharmaceuticals reported a better-than-expected quarterly profit and said it expected to repay more than $5 billion in debt earlier than it had targeted, sending its shares up 10 percent.
Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.
One of Papa's biggest challenges has been to cut the company's towering debt, which ballooned to nearly $30 billion following a spate of deal-making under former CEO Mike Pearson.
The company said on Tuesday it was continuing to reduce debt and resolve legacy issues, and that it expected to exceed its pledge to reduce $5 billion in debt earlier than February.
Valeant had long-term debt of about $28.5 billion as of June 30.
Last month, the drugmaker paid down $811 million of debt with proceeds from the sale of its cancer treatment unit Dendreon Pharmaceuticals, and agreed to sell its Obagi Medical Products business for $190 million. In June, Valeant agreed to sell its iNova Pharmaceuticals business for $930 million.
The maker of Bausch + Lomb contact lenses also lowered its revenue forecast for the year.
Valeant said it now expects revenue of $8.70 billion to $8.90 billion for the full year, compared with its previous forecast of $8.90 billion to $9.10 billion.
However, it maintained its 2017 forecast for adjusted earnings before interest, tax, depreciation and amortization.
Excluding items, the company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S. The beat was mainly due to strong sales of Valeant's irritable bowel syndrome drug Xifaxan.
Revenue of $2.23 billion was roughly in line with expectations.
On Monday, the FDA declined to approve Valeant's eye drop for the second time in a little over a year, raising concerns over Bausch + Lomb's manufacturing facility in Tampa, Florida.
U.S.-listed shares of the Laval, Quebec-based company were up about 10.3 percent at $16.96 in premarket trading on Tuesday.